title: Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
abstract: OBJECTIVE
  Convergent biological, epidemiological, and clinical data identified urate elevation as a candidate strategy for slowing disability progression in Parkinson disease (PD).
  
  
  OBJECTIVE
  To determine the safety, tolerability, and urate-elevating capability of the urate precursor inosine in early PD and to assess its suitability and potential design features for a disease-modification trial.
  
  
  METHODS
  The Safety of Urate Elevation in PD (SURE-PD) study, a randomized, double-blind, placebo-controlled, dose-ranging trial of inosine, enrolled participants from 2009 to 2011 and followed them for up to 25 months at outpatient visits to 17 credentialed clinical study sites of the Parkinson Study Group across the United States. Seventy-five consenting adults (mean age, 62 years; 55% women) with early PD not yet requiring symptomatic treatment and a serum urate concentration less than 6 mg/dL (the approximate population median) were enrolled.
  
  
  METHODS
  Participants were randomized to 1 of 3 treatment arms: placebo or inosine titrated to produce mild (6.1-7.0 mg/dL) or moderate (7.1-8.0 mg/dL) serum urate elevation using 500-mg capsules taken orally up to 2 capsules 3 times per day. They were followed for up to 24 months (median, 18 months) while receiving the study drug plus 1 washout month.
  
  
  METHODS
  The prespecified primary outcomes were absence of unacceptable serious adverse events (safety), continued treatment without adverse event requiring dose reduction (tolerability), and elevation of urate assessed serially in serum and once (at 3 months) in cerebrospinal fluid. RESULTS Serious adverse events (17), including infrequent cardiovascular events, occurred at the same or lower rates in the inosine groups relative to placebo. No participant developed gout and 3 receiving inosine developed symptomatic urolithiasis. Treatment was tolerated by 95% of participants at 6 months, and no participant withdrew because of an adverse event. Serum urate rose by 2.3 and 3.0 mg/dL in the 2 inosine groups (P < .001 for each) vs placebo, and cerebrospinal fluid urate level was greater in both inosine groups (P = .006 and <.001, respectively). Secondary analyses demonstrated nonfutility of inosine treatment for slowing disability.
  
  
  CONCLUSIONS
  Inosine was generally safe, tolerable, and effective in raising serum and cerebrospinal fluid urate levels in early PD. The findings support advancing to more definitive development of inosine as a potential disease-modifying therapy for PD.
  
  
  BACKGROUND
  clinicaltrials.gov Identifier: NCT00833690.
authors.affiliation: Massachusetts General Hospital, Boston, Massachusetts.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Schwarzschild
authors.affiliation: Harvard School of Public Health, Boston, Massachusetts.
authors.forename: Alberto
authors.initials: A
authors.lastname: Ascherio
authors.affiliation: Cornell University, New York, New York.
authors.forename: M Flint
authors.initials: MF
authors.lastname: Beal
authors.affiliation: Massachusetts General Hospital, Boston, Massachusetts.
authors.forename: Merit E
authors.initials: ME
authors.lastname: Cudkowicz
authors.affiliation: Brigham and Women's Hospital, Boston, Massachusetts.
authors.forename: Gary C
authors.initials: GC
authors.lastname: Curhan
authors.affiliation: University of Miami, Miami, Florida.
authors.forename: Joshua M
authors.initials: JM
authors.lastname: Hare
authors.affiliation: Thomas Jefferson University, Philadelphia, Pennsylvania.
authors.forename: D Craig
authors.initials: DC
authors.lastname: Hooper
authors.affiliation: University of Rochester, Rochester, New York.
authors.forename: Karl D
authors.initials: KD
authors.lastname: Kieburtz
authors.affiliation: Massachusetts General Hospital, Boston, Massachusetts.
authors.forename: Eric A
authors.initials: EA
authors.lastname: Macklin
authors.affiliation: University of Rochester, Rochester, New York.
authors.forename: David
authors.initials: D
authors.lastname: Oakes
authors.affiliation: University of Rochester, Rochester, New York.
authors.forename: Alice
authors.initials: A
authors.lastname: Rudolph
authors.affiliation: Georgetown University, Washington, DC.
authors.forename: Ira
authors.initials: I
authors.lastname: Shoulson
authors.affiliation: Peterborough, New Hampshire.
authors.forename: Marsha K
authors.initials: MK
authors.lastname: Tennis
authors.affiliation: University of Cincinnati, Cincinnati, Ohio.
authors.forename: Alberto J
authors.initials: AJ
authors.lastname: Espay
authors.affiliation: University of Cincinnati, Cincinnati, Ohio.
authors.forename: Maureen
authors.initials: M
authors.lastname: Gartner
authors.affiliation: Massachusetts General Hospital, Boston, Massachusetts.
authors.forename: Albert
authors.initials: A
authors.lastname: Hung
authors.affiliation: Massachusetts General Hospital, Boston, Massachusetts.
authors.forename: Grace
authors.initials: G
authors.lastname: Bwala
authors.affiliation: Scott & White Memorial Hospital/Texas A&M University, Temple.
authors.forename: Richard
authors.initials: R
authors.lastname: Lenehan
authors.affiliation: Scott & White Memorial Hospital/Texas A&M University, Temple.
authors.forename: Elmyra
authors.initials: E
authors.lastname: Encarnacion
authors.affiliation: Scott & White Memorial Hospital/Texas A&M University, Temple.
authors.forename: Melissa
authors.initials: M
authors.lastname: Ainslie
authors.affiliation: Scott & White Memorial Hospital/Texas A&M University, Temple.
authors.forename: Richard
authors.initials: R
authors.lastname: Castillo
authors.affiliation: University of Southern California, Los Angeles.
authors.forename: Daniel
authors.initials: D
authors.lastname: Togasaki
authors.affiliation: University of Southern California, Los Angeles.
authors.forename: Gina
authors.initials: G
authors.lastname: Barles
authors.affiliation: Butler Hospital, Providence, Rhode Island.
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Friedman
authors.affiliation: Butler Hospital, Providence, Rhode Island.
authors.forename: Lisa
authors.initials: L
authors.lastname: Niles
authors.affiliation: Oregon Health & Science University, Portland.
authors.forename: Julie H
authors.initials: JH
authors.lastname: Carter
authors.affiliation: Oregon Health & Science University, Portland.
authors.forename: Megan
authors.initials: M
authors.lastname: Murray
authors.affiliation: Rush University Medical Center, Chicago, Illinois.
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Goetz
authors.affiliation: Rush University Medical Center, Chicago, Illinois.
authors.forename: Jeana
authors.initials: J
authors.lastname: Jaglin
authors.affiliation: Cleveland Clinic, Cleveland, Ohio.
authors.forename: Anwar
authors.initials: A
authors.lastname: Ahmed
authors.affiliation: Institute of Neurodegenerative Disorders, New Haven, Connecticut.
authors.forename: David S
authors.initials: DS
authors.lastname: Russell
authors.affiliation: Institute of Neurodegenerative Disorders, New Haven, Connecticut.
authors.forename: Candace
authors.initials: C
authors.lastname: Cotto
authors.affiliation: Michigan State University, East Lansing.
authors.forename: John L
authors.initials: JL
authors.lastname: Goudreau
authors.affiliation: Michigan State University, East Lansing.
authors.forename: Doozie
authors.initials: D
authors.lastname: Russell
authors.affiliation: Struthers Parkinson's Center, Golden Valley, Minnesota.
authors.forename: Sotirios Andreas
authors.initials: SA
authors.lastname: Parashos
authors.affiliation: Struthers Parkinson's Center, Golden Valley, Minnesota.
authors.forename: Patricia
authors.initials: P
authors.lastname: Ede
authors.affiliation: Boston University, Boston, Massachusetts.
authors.forename: Marie H
authors.initials: MH
authors.lastname: Saint-Hilaire
authors.affiliation: Boston University, Boston, Massachusetts.
authors.forename: Cathi-Ann
authors.initials: CA
authors.lastname: Thomas
authors.affiliation: Boston University, Boston, Massachusetts.
authors.forename: Raymond
authors.initials: R
authors.lastname: James
authors.affiliation: Duke University, Durham, North Carolina.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Stacy
authors.affiliation: Duke University, Durham, North Carolina.
authors.forename: Julia
authors.initials: J
authors.lastname: Johnson
authors.affiliation: Duke University, Durham, North Carolina.
authors.forename: Lisa
authors.initials: L
authors.lastname: Gauger
authors.affiliation: Eastern Connecticut Neurology Specialists, Manchester.
authors.forename: J
authors.initials: J
authors.lastname: Antonelle de Marcaida
authors.affiliation: Eastern Connecticut Neurology Specialists, Manchester.
authors.forename: Sheila
authors.initials: S
authors.lastname: Thurlow
authors.affiliation: Parkinson's Disease & Movement Disorder Center of Boca Raton, Boca Raton, Florida.
authors.forename: Stuart H
authors.initials: SH
authors.lastname: Isaacson
authors.affiliation: Parkinson's Disease & Movement Disorder Center of Boca Raton, Boca Raton, Florida.
authors.forename: Lisbeth
authors.initials: L
authors.lastname: Carvajal
authors.affiliation: Ochsner Clinic Foundation, New Orleans, Louisiana.
authors.forename: Jayaraman
authors.initials: J
authors.lastname: Rao
authors.affiliation: Ochsner Clinic Foundation, New Orleans, Louisiana.
authors.forename: Maureen
authors.initials: M
authors.lastname: Cook
authors.affiliation: Ochsner Clinic Foundation, New Orleans, Louisiana.
authors.forename: Charlise
authors.initials: C
authors.lastname: Hope-Porche
authors.affiliation: Administrative Coordination Center, Massachusetts General Hospital, Boston.
authors.forename: Lauren
authors.initials: L
authors.lastname: McClurg
authors.affiliation: Administrative Coordination Center, Massachusetts General Hospital, Boston.
authors.forename: Daniela L
authors.initials: DL
authors.lastname: Grasso
authors.affiliation: Administrative Coordination Center, Massachusetts General Hospital, Boston.
authors.forename: Robert
authors.initials: R
authors.lastname: Logan
authors.affiliation: Clinical Coordination Center, University of Rochester, Rochester, New York.
authors.forename: Constance
authors.initials: C
authors.lastname: Orme
authors.affiliation: Clinical Coordination Center, University of Rochester, Rochester, New York.
authors.forename: Tori
authors.initials: T
authors.lastname: Ross
authors.affiliation: Clinical Coordination Center, University of Rochester, Rochester, New York.
authors.forename: Alicia F D
authors.initials: AF
authors.lastname: Brocht
authors.affiliation: Clinical Coordination Center, University of Rochester, Rochester, New York.
authors.forename: Radu
authors.initials: R
authors.lastname: Constantinescu
authors.affiliation: Clinical Coordination Center, University of Rochester, Rochester, New York.
authors.forename: Saloni
authors.initials: S
authors.lastname: Sharma
authors.affiliation: Clinical Coordination Center, University of Rochester, Rochester, New York.
authors.forename: Charles
authors.initials: C
authors.lastname: Venuto
authors.affiliation: Clinical Coordination Center, University of Rochester, Rochester, New York.
authors.forename: Joseph
authors.initials: J
authors.lastname: Weber
authors.affiliation: Clinical Coordination Center, University of Rochester, Rochester, New York.
authors.forename: Ken
authors.initials: K
authors.lastname: Eaton
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007288:Inosine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood* / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood* / Q000134:cerebrospinal fluid*
chemical_list: D015415:Biomarkers; D014527:Uric Acid; D007288:Inosine